Zhigancao decoction alleviates Parkinson's disease via inhibiting TNF/NF-κB and Ras/ERK-mediated neuroinflammation and apoptosis.
Zhigancao decoction alleviates Parkinson's disease via inhibiting TNF/NF-κB and Ras/ERK-mediated neuroinflammation and apoptosis.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Nanjing, CN · Author affiliation
Department of Neurology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons, with neuroinflammation and apoptosis serving as key pathological drivers. In this study, we investigated the traditional herbal formula Zhigancao Decoction (ZGCD) using an integrated strategy that combined network pharmacology prediction, experimental validation in MPTP-induced mouse and MPP+-treated cellular models, and molecular docking simulation. Our results demonstrate that ZGCD alleviates motor deficits and protects dopaminergic neurons by concurrently inhibiting the TNF/NF-κB and Ras/ERK signaling pathways, thereby reducing the release of pro-inflammatory cytokines and markers of apoptosis. In vitro experiments further confirmed that the bioactive components apigenin and bisdemethoxycurcumin contribute to this multi-pathway regulatory effect. This systems pharmacology approach elucidates how ZGCD simultaneously targets interconnected disease-relevant pathways, highlighting its potential as a multi-target therapeutic strategy for neurodegenerative disorders.